MarketCap
Eton Pharmaceuticals ETON
$ 58.86
44.26%
Facebook
X
Telegram
Eton Pharmaceuticals Gross Profit | ETON
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Eton Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.7 M | 23.4 M | 21.1 M | 14.3 M | 19 M | -397 K | 506 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.7 M | -397 K | 17.2 M |
Quarterly Gross Profit Eton Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 M | 14.7 M | - | 7.86 M | 11.9 M | 9.86 M | - | 6.3 M | 5.63 M | 5.01 M | - | 4.4 M | 9.68 M | 3.35 M | - | 2.02 M | 4.61 M | 1.33 M | - | 121 K | 2.89 M | 10.3 M | - | -17 K | -8 K | -3 K | - | 500 K | 500 K | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 M | -17 K | 4.93 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-1.72 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
6.31 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
9.02 K | - | 1.35 % | $ 17.8 M | China |
 |
Dynavax Technologies Corporation
DVAX
|
15.8 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
24.3 | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
Cerus Corporation
CERS
|
60.4 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
63.5 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Abcam plc
ABCM
|
270 M | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
325 M | - | - | - |  Russia |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
12.8 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
19.8 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
8.34 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |  Belgium |
 |
Anika Therapeutics
ANIK
|
63.8 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.94 M | - | -4.36 % | $ 27 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
-52.5 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
20.1 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
2.65 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 67.36 | 0.99 % | $ 12.9 B | USA |